AlzheimerAntecedentes y Terapias novedosas

  1. Miguel Ángel González Pérez 1
  2. Manuel Munuera Cabeza 1
  3. Guillermo Sánchez-Garrido Campos 1
  1. 1 Universidad Pablo de Olavide
    info

    Universidad Pablo de Olavide

    Sevilla, España

    ROR https://ror.org/02z749649

Revista:
MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

ISSN: 2173-0903

Año de publicación: 2018

Número: 29

Páginas: 17-23

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

Resumen

El Alzheimer es una enfermedad neurodegenerativa caracterizada por deterioros a nivel neurológico, muy presente en la sociedad actual y se ha intentado combatir con varios fármacos a lo largo de la historia mediante dos vías terapéuticas, siendo solo una de ellas la que más éxito ha cosachado, aunque la otra alternativa parece haber hallado la clave. De entre todos los tratamientos existentes, se mostrarán el fármaco Aducanumab y la terapia con Nanorods de oro, dos de las terapias más prometedoras. ¿Será suficiente como para alcanzar un tratamiento más efectivo contra el Alzheimer o habrá que seguir investigando otras posibles opciones?

Referencias bibliográficas

  • Hardy J., Allsop D. “Amyloid deposition as the central event in the aetiology of Alzheimer’s disease”. Trends in Pharmacological Sciences (1991). Volume 12: 383-388.
  • Hooper N. M. “Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prior protein”. Biochemical Society Transactions (2005). Volume 33: 335-338.
  • Hernández F., Ávila J., “Tauopathies”. Cellular and Molecular Life Sciences (2007). Volume 64: 2219-2233.
  • Wenk G. L., “Neuropathologic Changes in Alzheimer’s Disease”. J Clin Psychiatry (2003). Volume 64 (Supplement 9): 7-10.
  • Birks J., Harvey R. J. “Donepezil for dementia due to Alzheimer’s disease”. The Cochrane Database of Systematic Reviews (2006), Issue 1. Article nº: CD001190.pub2.
  • Birks J., Grimley Evans J. “Rivastigmine for Alzheimer’s disease”. Cochrane Database of Systematic Reviews (2015), Issue 1. Article nº: CD001191.pub4.
  • Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Jörg Möbius H. “Memantine in Moderate-to-Severe Alzheimer’s Disease”. The New England Journal of Medicine (2003). Volume 348 (Number 14): 1333-1341.
  • Tariot P. N., Farlow M. R., Grossberg G. T., Graham S. M., McDonald S., Gergel I. “Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil. A Randomized Controlled Trial”. JAMA: The Journal of the American Medical Association (2004). Volume 291 (Number 3): 317-324.
  • Sevigny J., Chiao P., Bussière T., Weinreb P. H., Williams L., Maier M., Dunstan R., Salloway S., Chen T., Ling Y., O’Gorman J., Qian F., Arastu M., Li M., Chollate S., Brennan M. S., QuinteroMonzon O., Scannevin R. H., Moore Arnold H., Engber T., Rhodes K., Ferrero J., Hang Y., Mikulskis A., Grimm J., Hock C., Nitsch R. M., Sandrock A. “The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease.” Nature (2016) Volume 537: 50-56.
  • Bohrmann, B.et al. “Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β”. J. Alzheimers Dis.(2012) Volume 28: 49–69.
  • Link S, El-Sayed MA. “Optical properties and ultrafast dynamics of metallic nanocrystals”. Annu Rev Phys Chem 2003; 54: 331-66.
  • Adura C, Guerrero S, Salas E, Medel L, Riveros A, Mena J, et al. “Stable conjugates of peptides with gold nanorods for biomedical applications with reduced effects on cell viability.” ACS Appl Mater Interfaces 2013; 5: 4076-85.
  • Guerrero S, Araya E, Fiedler JL, Arias JI, Adura C, Albericio F, et al.”Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide”. Nanomedicine (Lond) 2010; 5: 897-913.
  • Liao YH, Chang YJ, Yoshiike Y, Chang YC, Chen YR. “Negatively charged gold nanoparticles inhibit Alzheimer's amyloidbeta fibrillization, induce fibril dissociation, and mitigate neurotoxicity”. Small 2012; 8: 3631-9.
  • Araya E, Olmedo I, Bastus NG, Guerrero S, Puntes VF, Giralt E, Kogan MJ. “Gold Nanoparticles and Microwave Irradiation Inhibit Beta-Amyloid Amyloidogenesis”. Nanoscale Research Letters 2008; 3: 435-443
  • Kogan MJ, Bastus NG, Amigo R, Grillo-Bosch D, Araya E, Turiel A, et al. “Nanoparticle-mediated local and remote manipulation of protein aggregation”. Nano Lett 2006;6: 110-5.
  • Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, et al.. “Involvement of the low-density lipoprotein receptorrelated protein in the transcytosis of the brain delivery vector angiopep-2”. J Neurochem 2008;106: 1534-44. .
  • Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. “Identification and design of peptides as a new drug delivery system for the brain”. J Pharmacol Exp Ther 2008;324: 1064-72
  • Xue D, Zhao M, Wang YJ, Wang L, Yang Y, Wang SW, “et. A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Abeta42-induced cytotoxicity and increasing microglial phagocytosis”. Neurobiol Dis 2012;46: 701-9.
  • Funke SA, Bartnik D, Gluck JM, Piorkowska K, Wiesehan K, Weber U, et al. “Development of a small D-enantiomeric Alzheimer's amyloid-beta binding peptide ligand for future in vivo imaging applications”. PLoS One 2012; 7: e41457.
  • Wiesehan K, Stohr J, Nagel-Steger L, van Groen T, Riesner D, Willbold D. “Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide”. Protein Eng Des Sel 2008; 21: 241-6.
  • Kaletta T, Hengartner MO. “Finding function in novel targets: C. elegans as a model organism”. Nature Reviews Drug Discovery 2006; 5: 387-399.
  • Godyń J, Jończyk J, Panek D, Malawska B. “Therapeutic strategies for Alzheimer's disease in clinical trials”.
  • Novak, P. “Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial”. Lancet Neurology. 2016.
  • Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. “Firstin-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model”
Fuente de los datos: Dialnet